SynthesisFrontiers in medicine2025
A meta-analysis of randomized controlled trials examining the effectiveness of carbetocin in reducing intraoperative blood loss during abdominal myomectomy.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to systematically review and meta-analyze randomized controlled trials (RCTs) assessing the clinical efficacy and safety of carbetocin compared to passive control (placebo or no treatment) in the context of abdominal myomectomy. Methods: Six sources of information underwent screening until 13 April 2024. The risk of bias was assessed using the Cochrane Collaboration tool. The results were presented as mean difference (MD) or risk ratio (RR) along with a 95% confidence interval (CI) using a random-effects model. Results: Five RCTs with 6 arms and 484 patients (carbetocin = 262 and control = 222) were analyzed. The overall risk of bias was "low" in two studies and "some concerns" in three studies. The carbetocin group exhibited significantly lower mean intraoperative blood loss ( Conclusion: Carbetocin use was tolerable and associated with considerable declines in intraoperative blood loss and related complications compared with passive control intervention during abdominal myomectomy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.